Want to see MBRX full AI Analyst Report?
MBRX Stock Chart & Stats
$2.42
-$0.01(-0.56%)
At close: 4:00 PM EST
$2.42
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$1.79 - $21.51
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$11.21M
Enterprise Value-$0.55
Total Cash (Recent Filing)$10.32M
Total Debt (Recent Filing)$326.00K
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 19, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.98
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.00Price Target Upside561.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial Efficacy (Annamycin)Robust interim efficacy signals in the pivotal MIRACLE trial against control suggest Annamycin may materially improve remission rates in relapsed/refractory AML. If sustained through pivotal readouts, this durable clinical advantage increases the probability of regulatory approval, partner interest, and a meaningful long-term commercial opportunity in a high unmet-need niche.
Favorable Cardiac Safety ProfileDemonstrated lack of cardiotoxicity versus traditional anthracyclines is a structural competitive advantage that can expand Annamycin use in heavily pretreated patients and enable higher cumulative dosing. This safety differentiation supports broader clinical adoption, easier trial enrollment, and a stronger reimbursement case if efficacy is confirmed long-term.
Strengthened Patent ProtectionExpanded IP coverage, including a new Hong Kong patent, materially strengthens long-term exclusivity in key Asia-Pacific markets. Durable patent protection to 2040 enhances licensing and partnering leverage, supports commercialization planning across regions, and increases the potential lifetime value of Annamycin for investors and strategic collaborators.
Bears Say
No Product RevenueAs a clinical-stage biotech with no commercial products, Moleculin lacks recurring product revenue, making its long-term viability contingent on trial success, partnerships, or milestone receipts. This structural absence of revenue increases binary outcome risk and means future valuation depends on successful development or external deals rather than operating cash flow.
Sustained Cash BurnPersistent negative operating and free cash flow at a material multi‑million annual pace creates ongoing financing needs. Over the medium term this constrains strategic flexibility, elevates dilution risk, and could force pacing changes or program prioritization if external capital is tightened, directly impacting the timeline to potential commercialization.
Reliance On Dilutive FinancingRecent warrant exercises that modestly increased the share count highlight dependency on dilutive funding to support operations. Coupled with a shrinking equity/assets base, this structural reliance on equity raises the risk of further dilution, reduces per-share upside for investors, and may limit the company's ability to negotiate favorable non-dilutive partnership terms.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $1.79 and its highest was $21.51 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $11.21M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 15, 2026. The company reported -$3.54 earnings per share for the quarter, missing the consensus estimate of -$2.333 by -$1.207.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -1.61.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 5,336,350 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$3.54 in its last earnings report, missing expectations of -$2.333. Following the earnings report the stock price went down -4.091%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MBRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(561.16% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
0.56% Mutual Funds
1.41% Other Institutional Investors
96.14% Public Companies and
Individual Investors